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COMPARING THE EFFICACY OF ULTR?-BRIEF PULSE TO BRIEF PULSE IN 
?ELECTROCONVU?SIVE THERAPY FOR MAJOR DEPRESSION: A 
SYSTEMATIC REVIEW  
RAMKUMAR BALASUBRAMANIYAN 
ABSTRACT 
Background 
 Electroconvulsive therapy (ECT) is an effective intervention for major depressive 
disorder, especially for subsets of depression that resist more common therapies. 
However, ECT use is limited by its significant risk for adverse cognitive side effects. 
Shortening the pulse width of the current used has been demonstrated to lower this risk; 
however, the shorter pulse may not sufficiently elicit therapeutic effects. A systematic 
review was performed to determine if UBP ECT is as efficacious as BP ECT, and 
therefore would be a valid treatment for managing depression.       
Methods 
We conducted a literature search of MedLine/PubMed, Embase, Cochrane 
CENTRAL, and Google Scholars databases in October 2017 with the terms “depression”, 
“major depressive disorder”, “electroconvulsive therapy”, “ECT”, “brief”, “ultrabrief”, 
and “sine wave”. Studies were selected using inclusion criteria and exclusion criteria. 
Effects sizes were calculated from formalized mood rating pre-ECT and post-ECT, 
response rates and remission rates. Heterogeneity and reporting bias of the articles were 
also assessed. Data were analyzed using meta-analysis tools provided by the Erasmus 
Research Institute of Management.  
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Results  
Data from 9 studies resulted in a pooled Cohen’s d = 0.16 (CI = -0.08 to 0.43, p = 
0.149). The effect size alone favors BP ECT over UBP ECT in improving mood as per 
MADRS/HRSD ratings, but if given p > 0.05, results were non-significant. BP ECT was 
determined to be more efficacious then UBP ECT in terms of both achieving response 
and achieving remission, with a pooled ORresponse = 0.72 (CI – 0.49 to 1.05, p = 0.027) 
and pooled ORremission = 0.65 (CI = 0.42 to 0.98, p = 0.011).  
Conclusion 
The choice to use BP ECT or UBP ECT is a balance between the burden of side 
effects and efficacy. These data suggest that patients with a lower risk of developing 
cognitive side effect and/or need urgent intervention receive BP ECT. Conversely, 
patients with a higher risk of developing adverse cognitive side effects and/or are not in 
need of urgent intervention may benefit UBP ECT. Additional studies are recommended 
to confirm these findings and clarify the optimal use of these two modalities of ECT.  
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INTRODUCTION 
Pathophysiology of Depression 
Major depressive disorder (MDD) is a prevalent mental health disorder that 
affects 16 million Americans each year and as many 300 million people worldwide. By 
2020, the World Health Organization projects that depression will be the second most 
costly disease (as measured by Disability-Adjusted-Life-Year or estimated years of 
“healthy” life lost) and in the US alone, MDD is estimated to cost the economy $83 
billion annually34. Although the symptoms of depression are complex, it is typically 
characterized by a persistent feeling of sadness and loss of interest with associated 
disorders of mood, changes in sleep, decreased concentration, changes in appetite, and/or 
reduced energy level. Suicidal ideation is also commonly associated with depression; an 
estimated 50% of suicide victims have some form of depression14. Thus, MDD is a 
potentially life-threatening disorder whose symptoms are often a cause for immediate 
clinical intervention.   
The etiology of depression is complex; its heterogeneity makes it difficult to 
elucidate a unifying theory to its cause, which by extension can make the management of 
MDD difficult. Current theories of depression encompass neurobiological, genetic, 
developmental and psychosocial factors48. However, the developments of antidepressant 
drugs, behavior therapy and brain stimulation therapies have enabled clinicians to 
effectively manage depression in a large number of patients with MDD.  
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 Not everyone is equally susceptible to MDD, and the variance in the population is 
attributable to the genetic and environmental component of depression. A meta-analysis 
investigating the genetic epidemiology of depression indicated genetic factors contribute 
around 30-40% of the variance in susceptibility to depression, while psychosocial 
stressors, such as childhood sexual abuse, low social support, divorce, or other 
interpersonal difficulties, explains the remaining 60-70%93. Intervention via targeted 
genetic therapy is currently not a viable treatment option as there is no evidence for 
specific genes linked to the pathophysiology of depression. However, there is 
considerable benefit in psychosocial intervention via interpersonal or cognitive behavior 
therapies (CBT). A meta-analysis investigating CBT efficacy in depression found that 
CBT had a Number Needed to Treat (NNT) of 2.75, or in other word, for every 2.75 
patients treated with CBT, one will get better solely due to CBT alone22. For comparison, 
anti-hypertensive drug efficacy in severe hypertension produces a NNT of 15. 
While efficacious, behavior therapies do not completely manage all types of 
depression alone, so there is a critical need for neurobiological approaches. For a long 
time it was difficult to associate depression with gross brain pathophysiology as there 
were no viable non-invasive methods to study the brain architecture of living depressed 
patients. However, with the advent of neuroimaging techniques, researchers have been 
able to study both structural and functional changes associated with depression. Studies 
have found changes in four brain regions/systems to be typically associated with 
depression: the frontal lobes, temporal lobes, stress response by the HPA axis and 
mesolimbic dopamine system21, 23, 28, 29. More recently, there has been increasing focus on 
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the role of dysfunctional GABA/glutamate neurotransmission. Elucidating these changes 
have enabled researchers to have a better understanding of MDD- related dysfunctions, 
the mechanisms by which current efficacious therapies address these dysfunctions, and 
even provide avenues for potential therapies.      
Volumetric changes have been noted in the brains of patients with MDD. 
Numerous studies have noted decreased volume in the dorsolateral, orbitofrontal, ventral 
frontal, subgenual prefrontal cortex (PFC), hippocampus and parahippocampal gyrus in 
severely depressed patients12, 21, 29, 48. Findings of decreased volume in the hippocampus 
have especially been significant, as it has been suggested as a strong early marker for 
onset of MDD30. Conversely, an increased volume of the amygdala has been found in 
brains of patients with MDD, which correlates positively with the severity of depression 
symptoms24. While a majority of changes have been noted in cortical structures, recent 
studies have indicated there may be volumetric changes in subcortical structures, 
including the putamen and thalamus53.   
Beyond volumetric changes, functional imaging techniques such as fMRI and 
PET have allowed researchers to investigate abnormal brain activity in depressed 
patients67. This is generally done by monitoring brain activity while at rest or when the 
patient does emotional (match faces to emotions, judge positivity of negativity of a 
picture, etc.) or cognitive tasks (verbal memory tasks, mental arithmetic, etc.). Functional 
changes have been noted in several regions, especially those implicated in information 
processing, memory processing, and emotion/facial recognition. When compared to 
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healthy controls, studies have found, at rest, decreased activation in superior temporal, 
subgenual anterior cingulate (ACC), and middle frontal region while an increased 
activation was noted in the amygdala, para-hippocampus, posterior cerebellum, putamen, 
and thalamus21, 28, 67. When prompted with emotional stimuli, researchers noted altered 
processing in the ventral and orbital frontal cortex, decreased activation the ACC and 
putamen, and increased activation in the thalamus, para-hippocampus and globus pallidus 
as compared to healthy controls28, 67. When prompted with cognitive stimuli on the other 
hand, studies have noted increased activation in the middle/medial frontal cortex and 
putamen, and decreased activation in the inferior frontal cortex as compared to healthy 
controls20, 67.  
In addition to altered functioning within a region of the brain, studies have 
demonstrated that depressed patients have altered functional connectivity (interregional 
relationships between spatially separated regions of the brain). Two brain networks in 
particular, the Cognitive Control Network (CCN) and Default Mode Network (DMN), 
which are anatomically composed of fronto-parietal brain regions like the ACC and 
dorsal PFC, are dysregulated in patients with depression75. Currently the nature of CCN 
dysregulation is still unclear, as most studies report decreased connectivity but a smaller 
number of studies also report increased connectivity41, 44, 85 in patients diagnosed with 
major depressive disorder. MDD has been associated with increased functional 
connectivity in the DMN, especially in the anterior regions17 (which includes the medial 
prefrontal cortex and anterior cingulate cortex).     
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Dysregulation of the hypothalamus pituitary adrenal axis (HPA axis) has been 
consistently found in depressed patients. The HPA axis normally has a tightly regulated 
response to stress, culminating in release of cortisol which exerts a negative feedback 
control on the hypothalamus. Researchers have demonstrated the HPA axis is 
hypersensitive to stressors in depressed patients. Furthermore, dexamethasone 
suppression tests suggest negative feedback mechanism is dysfunctional, leading to 
chronically elevated levels cortisol. An estimated 40%-60% of depressed patients suffer 
from hypercortisolemia or other symptoms associated with dysfunctional HPA axis61. 
Elevated levels of glucocorticoids, particularly cortisol, have been postulated to exhibit 
neurotoxic effects and offer a potential etiology to the neuron loss noted in regions like 
the hippocampus12.  
The role of imbalances in neurotransmitters in depression has been of great 
interest to researchers, particularly for its pharmacological implications. The most 
pharmacologically successful intervention for depression is based on increasing synaptic 
levels of monoamines; virtually all compounds that act to elevate levels of monoamines 
have acute antidepressant effects. In fact, the significant clinical success of these anti-
depressant drugs have led to the monoamine-deficiency theory of depression, which 
states that the underlying pathophysiologic basis for depression is the decreased 
concentration of monoamine neurotransmitters in the central nervous system19.  
Drug manufacturers have mostly focused on modulating serotonin levels for many 
decades, but there has been a growing interest in the role of dopamine in depression. The 
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dopamine mediated mesolimbic reward circuit is implicated in several processes that are 
impaired in depression, including motivation, pleasure, concentration and energy level23. 
It has been proposed that the downregulation of this pathway is due to depression related 
stress response. Initially, the mesolimbic reward circuit is activated by stress, potentially 
as a coping mechanism to increase the individual’s motivation and drive. However, after 
this initial stress induced activation of the pathway, there seems to be a long-term 
downregulation of dopaminergic neuron activity, possibly as a compensatory response to 
the initial increase. This downregulation persists even after stressor withdrawal, leading 
overall to decreased activation of the mesolimbic dopamine reward circuit consistent with 
depression35. Furthermore, hyper-activation of the amygdala also inhibits dopaminergic 
neuron activity in the reward circuit9, 35.    
Although monoamines have been the target for much of the clinical management 
of depression, they do not comprise the majority of the neurotransmission in the brain. 
Glutamate, which is present in 85% of all synapses in the brain, is the major excitatory 
neurotransmitter and GABA, which is present in 40% of all neurons, is the major 
inhibitory neurotransmitter83. These neurotransmitters, for the most part, were not an area 
of significant interest in depression research until it was found that the drug ketamine had 
acute antidepressant effects in 20009. The efficacy of ketamine, a NMDA glutamate 
receptor antagonist, suggested a possible role for glutamate in depression. This triggered 
a significant amount of research into glutamate signaling in depression, as well as GABA 
signaling, since GABA is a product of glutamate metabolism. Fosse et al have noted 
reduced levels of glutamate in the ACC, DPFC, dorsal medial PFC, and ventral medial 
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PFC in patients with MDD29. Conversely, glutamate levels have been found be to 
elevated in occipital and parietal regions as well as subcortical structures such as the 
hippocampus and amygdala83. GABA has been found to be significantly reduced in the 
ACC, occipital cortex, and possibly dorsomedial/dorsolateral PFC, although findings on 
the latter are inconsistent29, 54. These findings offer an alternative route for development 
of pharmacological therapies.      
Despite the success pharmacological interventions, antidepressants are not a 
panacea for depression as certain subsets of the disease have a partial or full resistance to 
these drugs.  McIntyre and associates estimate that at least half of all patients with major 
depressive disorder will relapse or not achieve remission after multiple trails of 
antidepressants59. Furthermore, up to 20% of patients diagnosed with major depressive 
disorder have treatment resistant depression62 (typically defined as no response to at least 
two different antidepressants). The prevalence of treatment resistant depression prompts 
the need for alternative non-pharmacological therapies. One type of efficacious treatment, 
as discussed above, are behavior therapies like CBT. Another successful alternative 
approach is electroconvulsive therapy (ECT), where a small electric current is applied to 
the brain to induce seizures. In the modern clinical setting, patients with depression that 
have undergone ECT have demonstrated rapid and significant improvement in symptoms, 
to such a degree in fact, ECT is arguably the most effect treatment for depression 
available today47, 66, 76, 96.  
Historical Background of Electroconvulsive Therapy 
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The idea of inducing seizures to treat psychiatric conditions has been around as 
least since the 16th century, when Swiss physician Paracelsus orally administered the 
terpenoid camphor to produce seizures. However, despite its use as a convulsive agent, it 
did not reliably induce seizures, and physicians were often forced to administer multiple 
doses of camphor to produce the desired effect. With the development of machines that 
directed electrical impulses to the brain in the form of sine waves, clinicians found a new, 
more reliable way to elicit seizures. In April of 1938, Ugo Cerletti and Lucio Bini 
administered the first ever documented ECT treatment to a delusional, catatonic man. The 
patient showed marked improvement after even just one session, and after eleven 
sessions was discharged in remission. By the 1950s, ECT had emerged as a principal 
intervention for a wide range of psychiatric illnesses26, 27.  
However, the early ECT treatments were delivered without anesthesia or adequate 
ventilation, resulting serious adverse effects. Tonic clonic movements of the extremities 
were associated with seizures, and often they were so violent patients suffered bone 
fractures, dislocations and other musculoskeletal complications. Patients had to be 
physically restrained with straps to prevent self-harm from these convulsions, however, 
this also contributed to their discomfort and anxiety. Reports from this time indicate as 
much 80% of patients had feelings of anxiety and fear prior to ECT treatments31. Even 
the therapeutic effects of the electricity were tempered by serious adverse cognitive 
effects, as the sine waves used delivered a high amount of energy to the brain in a rapid 
period of time. In this period of time predating anesthesia, serious complications occurred 
as much as 40% of the time27. During the 1950s and 1960s, the public’s perception of 
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ECT slowly shifted from an effective, miracle therapy to a dangerous, damaging 
practice40.  
In the 1950s, anesthesia became more readily available, which significantly 
reduce complications associated with ECT and improve the overall patient experience. In 
1951, succinylcholine is introduced as the standard agent for muscle relaxation, 
preventing the violent convulsions that contributed to musculoskeletal complications. 
(curare was used as a muscle relaxant since the 1940s, but after a series of fatalities it was 
discontinued). Despite these improvements, public perception of ECT remained negative. 
This was reinforced by dramatic media depictions of outdated, unmodified ECT, leading 
many to view the practice as causing irreversible brain damage and even almost barbaric. 
These factors, along with the introduction of antidepressants, lead to the diminishing use 
of ECT. By the 1970s, many psychiatry programs removed ECT from their curriculum, 
and the practice was nearing obsolescence.  
Two major factors contributed to the re-emergence of ECT in the 1980s, and its 
subsequent re-establishment as a valid treatment option for psychiatric illnesses. First, 
clinicians became more knowledgeable about the limitations of antidepressants and other 
treatments, such as delayed onset, limited efficacy in managing treatment resistant 
depression, and medication toxicities. Second, ECT was re-examined by both 
professional psychiatric organizations and individual researchers, and there was a greater 
push to educate the public on the benefits and risks of modern ECT. Spearheaded by Dr. 
Max Fink and Dr. Harold Sackeim, there was greater scientific research into ECT, 
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leading to numerous publications that not only demonstrated the efficacy of ECT, but 
also acknowledged side effects and proposed a number of refinements to improve ECT 
technique even further26, 27, 40.  
Modern ECT has drastically improved in safety as compared to early, unmodified 
ECT; risks of serious complications dropped to 1 in 1,000 patients (comparable in risk to 
a minor surgical procedure). In the US, ECT treatments are typically done three times per 
week for a total of 6 to 12 treatments. There are several possible electrode configurations, 
but the two most commonly used are bilateral (BL) and right unilateral (RUL). One 
common strategy of dosing is a fixed high dose is administered to all patients (typically 
with unilateral electrode placements), but often the dose administered is not uniform. 
Typically clinicians will take one of two approaches to determine the individualized dose. 
In the first approach, dose is calculated based on age, gender, electrode placement, and/or 
medications that the patient is currently taking, while the second approach is to 
administer dose as a multiple of the minimal dose needed to induce a seizure4. Currently, 
around 100,000 patients undergo ECT treatment in the US annually, and it has become a 
permanent fixture in psychiatry programs worldwide45. 
Clinical Use of ECT and Stimulus Parameters 
 In the past 60 years, a large amount of data has been amassed in support of ECT 
efficacy in depression. Effectiveness of ECT has been demonstrated in both uncontrolled 
trails and trails using simulated-ECT treatment to control for non-specific effects 
associated with the ECT procedure, placebo or associated medications like anesthesia42, 
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73. Trials comparing ECT to psychotropic medications even suggest ECT superiority over 
pharmacological interventions. A 2003 systematic review and meta-analysis of 18 trials 
(n = 1144) calculated an effect size of 0.80 in favor of ECT comparing with 
pharmacotherapy, which suggests, on average, ECT is likely more clinically effective 
intervention than drug therapy96. It should be noted that although it boasts a robust 
immediate response, ECT tends to not be a permanent solution. In a 6 month follow-up, 
the overall relapse rates range from 50% to 80%, often requiring the patients to either 
repeat ECT treatment, pharmacotherapy, and/or maintenance ECT10. Nevertheless, ECT 
remains a gold standard treatment for depression.  
The therapeutic effect of ECT is dependent on a seizure being induced. This is 
evident from clinical trials where patients who administered doses below the seizure 
threshold, and therefore did not trigger seizure, did not have improvement in symptoms26. 
Eliciting a seizure via ECT involves complex and cumulative processes at the level of an 
individual neuron. In a controlled setting, an electrical potential is established across the 
scalp, which induces an electric field in the brain. Modern ECT machines use a train of 
rectangular pulses in alternating current direction. This electric field stimulates action 
potentials in neuronal axons. The activity of individual neurons becomes synchronized 
via synaptic interactions as well as non-synaptic effects. Repeated synchronized 
discharges induce epileptic activity, likely through potentiation of excitatory synapses 
and depotentiation of inhibitory synapse in a neural ensemble. On a macro level, this will 
elicit a grand mal seizure.  
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Despite widespread use of ECT, researchers have not been able to arrive at a 
consensus for the underlying mechanism of action. It is thought that the seizure itself is 
involved in changes that result in the therapeutic effects. However, even though a seizure 
is necessary to have a therapeutic effect, it is not sufficient. This has been demonstrated 
by applications of low dose brief pulse RUL-ECT and low dose ultrabrief pulse BL-ECT, 
which are therapeutically ineffective despite eliciting seizures78, 79, 81. Conversely, studies 
investigating supra-threshold ECT on the other hand have demonstrated markedly 
improved efficacy80,82. This suggests the therapeutic role of the electrical stimulus is not 
just an ictal trigger, but may induce dose dependent changes to the neurophysiology of 
the patient.  Through neuro-imaging and power spectral analysis of EEG, researchers 
have been able to illustrate the structural and functional changes associated with ECT 
treatments, especially in the areas typically associated with depression. Converging 
evidence suggests that ECT elicits an effect in which underlying dysfunctions in neural 
circuitry are corrected. Specifically, Fosse and associates hypothesize that the anti-
depressive effects of ECT are mediated by corrective changes in the six brain regions or 
systems as described above: the frontal lobe, temporal lobe, HPA axis, mesolimbic 
dopamine system, glutamatergic system, and GABA neurotransmission29.  
ECT seems to alter aberrant activity in frontal cortices, temporal lobes and the 
hippocampus. Henry et al reported, after end of ECT treatment, there was reduced 
activity in the left posterior frontal region, right PFC and right parietal lobes, which 
correlated with reduced depression scores38. Nobler et al noted deactivation in the both 
the bilateral frontal cortices and anterior temporal cortices for up to 1 week post-ECT 
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treatment, again correlating with reduced depressions scores29. ECT has also been 
demonstrated to normalize aberrant interregional connectivity. Perrin et al noted a 
reduction in functional connectivity from the left dorsolateral PFC to other cortico-limbic 
structures, which displays hyper-connectivity in patients with MDD69. Functional 
connectivity is also increased in certain region, as demonstrated by Wei et al who noted 
increased connectivity to the middle frontal gyri, an area associated with emotional 
regulation99.   
 
Figure 1. Functional Connectivity to Dorsolateral Prefrontal Cortex pre-ECT and 
post-ECT. Orange areas denote connectivity with DLPFC pre-ECT in patients with 
MDD, blue areas indicated connectivity with DLPFC post-ECT. The z values are 
distance (mm) from the midline as defined by the MNI. Adapted from Perrin et al 201269. 
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Numerous studies have found a reduced cortisol response in dexamethasone 
suppression tests, which suggests correction of the dysregulated HPA axis response to 
stress94, 98. Interestingly, it seems that ECT strongly activates the HPA axis as there is an 
initial hypersecretion of ACTH, cortisol and prolactin that returns to baseline condition 
within a few hours post-ECT37. These values are calculated by normalizing the response 
to baseline. Re-establishment of normal regulation of the HPA axis leads to 
normalization of cortisol secretion. Thus, in addition to resolving the effects associated 
with HPA axis dysfunction, there is also reduced neurotoxicity (increased sprouting of 
mossy fibers) in the hippocampus.  
Similarly, ECT enhances/normalizes neurotransmission at the level of both 
neurotransmitter release and receptor response. Neuroimaging studies have indicated that 
ECT enhances monoamine neurotransmission in the brain via activation of serotonergic 
pathways and the mesolimbic dopamine system6, which may last, at the minimum, 
several days. Researchers have found 60-70% increase of cerebrospinal fluid levels of 
homovanillic acid (HVA), a dopamine metabolite and marker for dopamine turn-over, 
after competition of ECT treatment64, 76. ECT has also been implicated in enhancing 
dopamine function through modulating dopamine receptors18. ECT has been show to 
normalize glutamatergic alterations in specific frontotemporal networks29.  
Decreasing Pulse Width  
Despite the refinement in technique, ECT continues to be limited by extensive 
cognitive side effects, including anterograde/retrograde amnesia and postictal 
 15 
disorientation. While anterograde amnesia and postictal disorientation tend to resolve 
within one hour after ECT is completed, evidence suggests that retrograde amnesia is 
often longer lasting (hours to weeks). Studies report the disruption of memory is 
consistent with functional deactivation of hippocampal regions and memory processes 
like long term potentiation5, 8, 92. Unfortunately, these effects are induced by the very 
current needed elicit seizures and activate ECT’s therapeutic effects. Thus, researchers 
are trying to adjust various parameters of the current in an effort to reduce adverse 
cognitive effects while preserving efficacy  
 
Figure 2. Diagram comparing BP width with UBP width. Other parameters of current 
used in ECT are also illustrated. Adapted from Loo et al 201252. 
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Currently, the major parameter of interest to clinicians is the pulse width of the 
current used. Adjusting the current width is not a novel concept, as previously it was 
switched to a rectangular, brief width pulse (0.5 ms-1.5 ms) from the much higher energy 
sinusoidal waves after it was demonstrated that brief pulse (BP) ECT can match the 
traditional sinusoidal wave ECT with significantly less adverse cognitive effects47, 90. It 
has been demonstrated that the average neuron only requires a current of roughly 0.1 ms 
to 0.2 ms to be sufficiently depolarized, much wider than the width of the standard brief 
pulse (0.5 to 1.5 ms). In practice, ~0.1 ms is too small to elicit a seizure, but researchers 
have managed to narrow it down to 0.3 ms, known as ultrabrief pulse. Ideally, the smaller 
width would allow neurons to be more efficiently depolarized and other brain structures 
such as the hippocampus or temporal lobe structure to be spared33. This is demonstrated 
by current density maps comparing 1 ms pulse-width and 0.6 ms pulse-width, in which a 
smaller area of the brain is directly activated with narrower pulse, and therefore 
stimulation becomes more focal (see fig. 3). This map also shows action potentials are 
generated in brainstem with the longer pulse, consistent with brief pulse activating 
structures other than in the desired areas.  
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Figure 3. Snapshots of neural excitation in a RUL model with 1 ms and 0.6 ms 
pulse-widths. The arrow on the left indicates activation of the brainstem. The intensity 
wedge is provided on the right. Adapted from Bai et al 20127.  
 
Furthermore, studies have demonstrated that a narrower pulse requires less total energy to 
induce seizures than a longer pulse, with as much as 50% less electrical dose49, 50, 79.   
 In practice, all of this translates to ultrabrief (UB) pulse ECT having fewer 
adverse cognitive effects. A meta-analysis investigating cognitive effects of ECT showed 
UBP ECT was superior to BP ECT in terms of tolerability, with patients experiencing 
fewer memory and global cognitive issues (see fig. 4). However, there remained concerns 
about its relative efficacy as compared to BP, with some believing UBP ECT current 
would not cover sufficient area to elicit corrective structural and functional changes. 
Indeed, older studies concluded ultrabrief pulse was not as efficacious as brief pulse15, 74. 
However, upon retrospective review, these studies were found to be poorly controlled, 
did not account for multiple confounding variables, or used suboptimal doses. Still, 
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despite more recent trials indicating UBP ECT is more efficacious than previously 
thought, the question of which pulse width is superior remains. 
 
Figure 4. Forest plots of cognitive tests for RUL BP ECT versus RUL UBP ECT. 
Patients receiving RUL BP ECT report significantly fewer adverse cognitive effects. 
Patients were assessed at the end of an acute ECT course. Adapted from Tor et al95. 
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Specific Aims and Goals 
 ECT is a highly effective treatment for depression, particularly the subsets of 
depression that resist pharmacological intervention. However, it comes with the risks of 
significant adverse cognitive effects. Patients report both impairments in memory 
functioning and global cognition. Unfortunately these side effects limit ECT use, and 
prevent the full availability of this potentially life-saving intervention to every patient 
with depression.    
Researchers have made major developments in the past few decades to reduce the 
adverse effects while maintaining efficacy by modulating various aspects of ECT. One 
area of great interest is the reducing the width of the electrical pulses, since the standard 
BP width is, theoretically, much larger than it needs to be to excite neurons and generate 
a train of potentials. Studies into the shorter UBP have demonstrated shorter pulses result 
in fewer side effects. However, with increased safety come concerns that an UBP pulse 
may not deliver sufficient charge to elicit the therapeutic effects associated with BP ECT. 
Although there are randomized controlled trails investigating the efficacy of BP ECT and 
UBP ECT in treating depression and other psychiatric disorders, there is not currently a 
consensus on the superiority of one method over another.  
 The goal of this thesis is to examine the current body of evidence and provide an 
updated comparison of the efficacy of UBP ECT to BP ECT in treating depression. 
Accordingly, we carried out a systematic review and meta-analysis of randomized 
controlled trials comparing UBP ECT and BP ECT efficacy. Efficacy will be 
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quantitatively assessed with three outcomes: improvement in mood, success in achieving 
response, and success in achieving remission. Hopefully this thesis will provide an 
updated comparison of UBP ECT to BP ECT, and provide a clearer picture of UBP’s role 
in the modern clinical setting.        
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METHODS 
Search Strategy and Study Selection  
MedLine/PubMed, Embase, Cochrane CENTRAL, and Google Scholars were 
searched in October 2017 with the following keywords were used in combination: 
“depression” OR “major depressive disorder” AND “electroconvulsive therapy” OR 
“ECT” OR “brief” OR “ultrabrief” OR “sine wave”. Additional articles were included 
from references of previous systematic reviews on electroconvulsive therapy and 
depression as well other relevant studies. Studies were screened by two people separately 
using the Covidence software, including a board certified psychiatrist.   
To be included in this review studies had to meet the following criteria: (1) a 
double-blind, randomized controlled design; (2) at least one treatment group received 
wither UBP or BP (3) participants (of any age or gender) that have been diagnosed with 
depression (4) use of either Montgomery-Asberg Depression Rating Scale (MADRS) or 
Hamilton Depression Rating Scale (HDRS) to measure a formalized mood rating before 
and after ECT and (5) sufficient results that allow the calculation of Cohen’s d or odds 
ratio (OR).  
Studies were excluded if (1) they did not report the means of the mood ratings to 
calculate effect sizes (2) were not written in English (3) were not published, or in the 
process of publishing, in peer-reviewed journals (4) did not use primary data.  
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There were no restrictions on electrode placement across the studies, but the 
electrode placement within a study needed to be consistent among the treatment groups. 
There were also no restrictions on the length of the study, schedule of treatment, 
geographic location of study, publication status or publication date.  
Data Extraction and Calculating Effect Size 
In order to investigate efficacy, three different outcomes were evaluated: change 
in mean depression scores pre-ECT to post-ECT, remission rates and response rates. 
Depression scores that were rated within one week of the end of 6-8 ECT treatments were 
chosen for extraction. Either Cohen’s d or odds ratio (both ways to estimate effect size) 
were calculated to best quantify the differences between ultrabrief and brief efficacy, as 
well as reconcile the different psychometric scales used. All calculations for effect sizes, 
assessing bias and assessing heterogeneity were done using meta-analysis workbooks 
provided generously by Erasmus Research Institute of Management (ERIM). Forest plots, 
were generated with tools provided generously by DistillerSR and Erasmus Research 
Institute of Management.  
Cohen’s d was used to calculate the effect size for change in mood ratings from 
baseline, since MADRS/HRSD scores are continuous data. Cohen’s d, or standardized 
mean difference, is the difference in means over the pooled standard deviation; so, in 
order to calculate it, both the difference in mean of the change from baseline and standard 
deviation of the change from baseline were extracted. By assigning BP as the “control” 
group and UBP as the “treatment” group, the results can be described as such: d < 0 
 23 
suggests BP is superior, d = 0 suggests BP and UBP are equally effective, and d > 0 
suggests UBP is superior.    
The standard deviation of the change from baseline and/or means of the change 
from baseline were not always included. Alternatively, Cohen’s d can be calculated using 
the t-statistic, standard error, or p-value as per guidelines in the Cochrane Handbook for 
Systematic Reviews for Interventions39. If none of these values were included, the 
missing standard deviations can be imputed using the correlation coefficient, a value that 
describes how similar the baseline and final measurements are across participants.  
Remission rates are defined as the proportion of patients who scored MADRS 
<10 or HRSD <7 after the final ECT95. Response rates are defined as the proportion of 
patients who had ≥50% reduction on MADRS/HRSD score from pre-ECT to post-ECT. 
Both of these rates are dichotomous outcomes (a patient either fails or does not fail to 
achieve remission/response), so an odds ratio (OR) was selected to describe the effect 
size. Again, by assigning BP as the “control” group and UBP as the “treatment” group, 
OR is calculated as the ratio of odds of UBP ECT achieving remission/response to the 
odds of BP ECT achieving remission/response. The results can be described as such: 0 < 
OR < 1 suggests BP is superior, OR = 1 suggests BP and UBP are equally effective in 
terms of achieving remission/response, and OR > 1 suggests UBP is superior.  
Although OR is a mathematically rigorous measure, the result is often difficult to 
interpret in a clinical context84. Alternatively, with dichotomous data, the absolute risk 
ratio (ARR) can be calculated; this measure is the difference in event rates (i.e achieving 
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response/remission) between the treatment (UBP) and control (BP) groups. By taking the 
inverse of the ARR calculates a more clinically relevant measure, the Number Needed to 
Treat (NNT).  The NNT is defined as the average number of patients needed to be treated 
to have an improvement on one person. An NNT = 1 suggests everyone improves with 
treatment and no one improves with control, and as NNT increases, the treatment is 
considered less and less effective. Note that if this measure is negative, we cannot use 
NNT as it is always positive. In this case we would describe the measure as the Number 
Needed to Harm (NNH), defined as the number of patients needed to be exposed to 
treatment to have harm in one person. Converse to NNT, an NNH = 1 suggests everyone 
is harmed with treatment and no one is harmed with the control, and as NNH increases, 
the treatment is considered less and less harmful.  
Assessing Heterogeneity and Reporting Bias 
 Bias was visually assessed through with a funnel plot, as asymmetry in a funnel 
plot may indicate publication bias, selective outcome reporting, selective analysis 
reporting or other reporting biases91. The Egger’s linear regression test was also included 
to as a more rigorous assessment of funnel plot asymmetry. If the test provides a 
significant result (p<0.05), the funnel plot is asymmetric, and therefore there is likely 
bias, and conversely, is the test provides an insignificant result (p>0.05), there is unlikely 
to be bias. Heterogeneity, variation among studies greater than expected by chance alone, 
was also assessed. Given the relatively low number of studies included, we opted to 
include the I2 statistic to assess heterogeneity rather than the classical measure, Cochrane 
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Q. Heterogeneity was considered insignificant if I2 statistic was below 40%, moderate if 
between 30-60%, substantial if between 50-100%.  
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RESULTS 
Literature Search 
 
Figure 5. Flowchart of literature search and selection. We screened 885 articles and 
selected 9 appropriate papers. Adapted from Moher et al 200960.  
 
 A total of nine studies met the criteria as outlined above, and were suitable for 
inclusion in this systematic review. One study, Mayur et al 2011, which had 22 patients, 
10 (45.6%) receiving BP ECT and 12 (55.4%) receiving UBP ECT, did not include 
patient demographics. The remaining 8 studies had a total of 747 patients, 64.5% of 
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which were female and 35.5% of which were male, with an average age of 52.9. Of these 
patients, 293 (39%) received BP ECT and 456 (61%) received UBP ECT. Six studies, 
which used MADRS to rate mood, had a mean mood baseline score of 32.4, while the 
remaining the two studies, which used HDRS to rate mood, had a mean mood baseline 
score of 30.1.      
Efficacy Results 
 Data from 9 studies resulted in a pooled Cohen’s d = 0.16 (CI = -0.08 to 0.43, p = 
0.149). The effect size alone favors BP ECT over UBP ECT in improving mood as per 
MADRS/HRSD ratings, given p > 0.05, results were non-significant. Data from 7 studies 
were pooled to calculate OR for remission rates (ORremission) and data from 6 studies were 
pooled to calculate OR for response rates (ORresponse). BP ECT was determined to be 
more efficacious then UBP ECT in terms of both achieving response and achieving 
remission, with a pooled ORresponse = 0.72 (CI – 0.49 to 1.05, p = 0.027) and pooled 
ORremission = 0.65 (CI = 0.42 to 0.98, p = 0.011). ARRresponse = -0.08 (CI = -0.17 to 0.01, p 
= 0.022) and ARRremission = -0.10 (CI = -0.19 to -0.01, p = 0.003), so we choose NNH to 
arrive at NNH = 12.5 for response and NNH = 10 for remission. In other words, for every 
12.5 patients treated with UBP, we would expect one fewer response than if treated with 
BP. Similarly, for every 10 patient treated with UBP, we would expect one fewer 
remission than if treated with BP.  
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Table 1. Estimations of the effect size of change in mood from baseline for 9 selected 
trials. Lists study and associated Cohen’s d with confidence intervals and respective 
weights (defined as inverse of variance) 
 
 
 
 
 
Figure 6. Efficacy of BP ECT versus UBP ECT in depression as defined by the 
change in mood scores from baseline. On the x-axis is Cohen’s d, with BP favored 
when d < 1.00 and UBP favored when d > 1.00. On the y-axis is each corresponding 
study. Box size is proportional to respective weights. 
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Table 2. Estimations of the effect size of response rates for 6 selected trials. Lists 
study and associated odds ratio with confidence intervals and respective weights (defined 
as inverse of variance). 
 
 
Figure 7. Forest plot of efficacy of BP ECT versus UBP ECT in depression as 
defined as response rates. On the x-axis is the effect sizes, with BP favored when OR < 
1.00 and UBP favored when OR > 1.00. On the y-axis is each study listed with the 
number corresponding to the number in Table 3.  
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Table 3. Estimations of the effect size of remission rates for 7 selected trials. Lists 
study and associated odds ratio with confidence intervals and respective weights (defined 
as inverse of variance) 
 
Figure 8. Forest plot of efficacy of BP ECT versus UBP ECT in depression as 
defined as remission rates. On the x-axis is OR, with BP favored when OR < 1.00 and 
UBP favored when OR > 1.00. On the y-axis is each study listed with the number 
corresponding to the number in Table 3. 
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Heterogeneity and Bias   
 There is no evidence of reporting bias as visually assessed by the funnel plot (see 
fig. 3) or by Egger’s linear regression test (p = 0.69). Since I2 = 0.0%, any contribution to 
variation across studies due to heterogeneity is considered insignificant.  
 
 
Figure 9. Funnel plot with pseudo 95% confidence limits. Each selected study is 
included as its effect size against its standard error.  
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DISCUSSION 
Analysis of Data 
 Two out of the three outcomes of interest, response rates and remission rates, 
suggest BP ECT has better clinical outcomes than UBP ECT. Pooled ORresponse and 
ORremission, as well as their associated NNH, indicate BP ECT is more efficacious than 
UBP ECT. The third outcome of interest was not as definitive. The pooled Cohen’s d = 
0.16, so the mean improvement in mood at the 50th percentile of patients receiving BP 
ECT is equivalent to the 58th percentile of patients receiving UBP ECT. However, since p 
= 0.149, assuming the null hypothesis of “there is no difference in effect size between 
UBP ECT and BP ECT” is true, there is a 14.9% chance that the estimated effect size was 
due to chance alone; in other words, the results are statistically non-significant, and 
therefore we cannot state, conclusively, that BP ECT is more effective than UBP ECT as 
per change in mood ratings. Furthermore, the 95% confidence interval encompasses 
values that range from slightly favoring UBP ECT to no difference to  moderately 
favoring BP ECT (-0.08 to 0.43).   
Limitations 
 There are two potential limitations to this systematic review that may have 
affected the precision and accuracy of the meta-analysis. First, the selected trials had 
relatively small sample sizes, which present challenges to the statistical analysis of the 
data. With a smaller sample size we see greater variance, and as a result less precise 
estimations of the effect sizes. This is clearly illustrated by the relatively wide margin of 
the calculated 95% confidence intervals. A smaller sample size also leads to a higher 
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likelihood of a Type II error, or in other words, a higher likelihood of falsely concluding 
that there is no difference in means between UBP ECT and BP ECT. Furthermore, the 
relatively small sample sizes preclude subgroups analysis with factors such as optimal 
dosages relative to the seizure threshold as well as any examination of impact of 
moderator variables using linear regression.       
The second major limitation is the missing standard deviations; of the nine 
studies, six did not include the standard deviation for the change from baseline. As 
discussed in the methods section, it is possible to impute the desired standard deviation, 
but it needs to be noted that they are approximations that may not accurately reflect the 
true standard deviations. For one study, Sackeim et al 2008, we had to do multiple 
approximations as the standard deviation was calculated backwards from a given P value. 
In another study, Loo et al 2008, neither the final standard deviation nor any statistic that 
would have allowed an approximation was included (confidence intervals, standard error, 
t value, P value). In this case, the standard deviation was estimated similar results, as per 
the Cochrane Handbook; we opted to take the average of studies with similar sample 
sizes, baseline mood scores and final mood scores39. Overall, these approximations 
limited the accuracy of the study.   
Future Directions  
 Ideally, to derive more precise estimations of effect size, researchers should 
attempt more head-to-head studies comparing the efficacy of UBP ECT to BP ECT with 
larger sample sizes. Unfortunately, given the nature of ECT and the patient population, 
repeating randomized controlled trails with larger sample sizes is likely not feasible. Still, 
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repeat randomized controlled result in a greater number of observations, which can help 
improve the statistical significance of future meta-analyses.  
One potential area of interest is comparing the efficacy of UBP ECT to BP ECT 
after it was switched from BP or UBP ECT, respectively. Alternatively, efficacy of BP 
ECT switched from UBP ECT can be compared to UBP ECT alone. Given that the 
mechanisms behind the therapeutic effects of ECT have not been fully detailed, further 
studies investigating the structural and functional changes in UBP ECT, especially in 
context of the changes in BP ECT, can provide a better understanding of why BP ECT is 
more efficacious than UBP ECT. Furthermore, findings from research into BP ECT 
should not be directly applied to the treatment approach of UBP ECT; therefore all 
aspects of UBP ECT technique should be investigated further.   
Conclusion 
The data would indicate that it is reasonable to choose the treatment that shows 
superior efficacy, and, in this case it is BP ECT. However, BP ECT comes at cost, 
namely more adverse cognitive effects than UBP ECT. The superior tolerability of UBP 
ECT indicates it is a valuable modality that should be part of every clinician’s options for 
intervention. Thus, the choice to use BP ECT or UBP ECT is a balance between the 
burden of side effects and efficacy. It should be recommended that patients with a lower 
risk of developing cognitive side effect and/or need urgent intervention should receive BP 
ECT. Conversely, patients with a higher risk of developing adverse cognitive side effects 
and not in need of urgent intervention should receive UBP ECT. 
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